CME Group (NASDAQ: CME) revenue
CME Group reported revenue of $6,521m for fiscal 2025, 6.4% more than in fiscal 2024 ($6,130m). Since fiscal 2016 its revenue has grown by 81.4%, an average growth of 6.8% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $6,521m | +6.4% | $4,230m | 64.9% |
| 2024 | $6,130m | +9.9% | $3,932m | 64.1% |
| 2023 | $5,579m | +11.1% | $3,436m | 61.6% |
| 2022 | $5,019m | +7.0% | $3,016m | 60.1% |
| 2021 | $4,690m | −4.0% | $2,645m | 56.4% |
| 2020 | $4,884m | +0.3% | $2,637m | 54.0% |
| 2019 | $4,868m | +13.0% | $2,588m | 53.2% |
| 2018 | $4,309m | +18.2% | $2,608m | 60.5% |
| 2017 | $3,645m | +1.4% | $2,311m | 63.4% |
| 2016 | $3,595m | — | $2,201m | 61.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of CME Group
- How much revenue did CME Group make in fiscal 2025?
- CME Group reported revenue of $6,521m for fiscal 2025, compared with $6,130m in fiscal 2024.
- How much has the revenue of CME Group grown?
- Between fiscal 2016 and fiscal 2025 it went from $3,595m to $6,521m: 81.4% more, an average growth of 6.8% a year.
- What was the best year for revenue at CME Group?
- Of its last 10 fiscal years, fiscal 2025, with $6,521m.
- Where do the figures for CME Group come from?
- From the annual report (Form 10-K) that CME Group files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that CME Group files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on CME Group: the CME Group page · annual accounts · net income · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.